Skip to main content
. 2017 May 19;255(7):1259–1273. doi: 10.1007/s00417-017-3647-4

Fig. 4.

Fig. 4

Distribution of treatment intervals in patients receiving intravitreal aflibercept in the ATLAS study [89]